FDA grants priority review for Actemra to treat giant cell arteritis – Healio
Pulse Headlines |
FDA grants priority review for Actemra to treat giant cell arteritis
Healio The FDA has accepted Genentech’s supplemental biologics license application and has granted priority review for Actemra in the treatment of giant cell arteritis, according to a company press release. FDA grants priority review for Roche’s Actemra to treat giant cell arteritis FDA Grants Priority Review for Actemra for Treatment of Giant Cell Arteritis Tocilizumab Gets Priority Review for Treatment of Giant Cell Arteritis |
View original article
Author:
Powered by WPeMatico
Health Topic Contributor
Editors and curators bringing you the latest and most impactful health news. Truly objective, we print links to stories and studies that may contradict one another. If you're searching for news on health studies, alternative health modalities, facts on modern allopathic medicine, and more, we're you're team bringing you the stories and facts that matter.